GENERAL ASSEMBLY OF NORTH CAROLINA SESSION 2021

S 3

SENATE BILL 711

Judiciary Committee Substitute Adopted 7/1/21 Finance Committee Substitute Adopted 7/21/21

Short Title: 1	NC Compassionate Care Act.	(Public)
Sponsors:		
Referred to:		
	April 8, 2021	
	A DILL TO DE ENTETT ED	
ANI ACT ENIAC	A BILL TO BE ENTITLED CTING THE NORTH CAROLINA COMPASSIONATE CARI	ZACT
	Sembly of North Carolina enacts:	ZACI.
	CTION 1. Chapter 90 of the General Statutes is amended by add	ing a new Article
to read:	2110111. Chapter 70 of the General Statutes is afficilled by add	ing a new Article
to read.	"Article 5H.	
	"North Carolina Compassionate Care Act.	
"§ 90-113.110.	• • • • • • • • • • • • • • • • • • •	
	e shall be known and may be cited as the "North Carolina Cor	npassionate Care
Act."	· · · · · · · · · · · · · · · · · · ·	
	Legislative findings and purpose.	
	l Assembly makes the following findings:	
<u>(1)</u>	Modern medical research has found that cannabis a	ınd cannabinoid
	compounds are effective at alleviating pain, nausea, and	other symptoms
	associated with several debilitating medical conditions.	
<u>(2)</u>	As of May 2021, 36 states and the District of Columbia	
	state-level criminal penalties for the medical use, cultivation	
	of cannabis, and in enacting this Article, North Carolina n	
(0)	action to preserve and enhance the health and welfare of its	
<u>(3)</u>	This Article is intended to make only those changes to existing	_
	laws that are necessary to protect patients and their doctors f	
	civil penalties and is not intended to change current civil a	nd criminal laws
(4)	governing the use of cannabis for nonmedical purposes.	aa maxxamta amaat
<u>(4)</u>	The General Assembly enacts this Article pursuant to its poli- legislation for the protection of the health of its citizens, a	
	State in the Tenth Amendment of the United States Constitu	
"§ 90-113.114.		tion.
	ing definitions apply in this Article:	
(1)	Adequate supply. – An amount of usable cannabis derived	d solely from an
(1)	intrastate source that is possessed by a qualified patient	
	possessed by a qualified patient and the qualified patient	•
	caregiver, in an amount that does not exceed what is reasonable	
	assure the uninterrupted availability of cannabis for a period	
	form recommended by the qualified patient's physician for	



1		alleviating the symptoms or effects of the qualified patient's debilitating
2		medical condition.
3	<u>(2)</u>	Advisory Board The Medical Cannabis Advisory Board established in
4		G.S. 90-113.116.
5	<u>(3)</u>	Bona fide physician-patient relationship. – A treatment relationship between
6		a physician and a patient in which the physician has completed a full
7		assessment of the patient's medical history, including checking the patient's
8		prescription history in the Controlled Substances Reporting System, and
9		current medical condition, including an in-person physical examination, and
10		the physician is available or offers to provide follow-up care and treatment to
11		the patient, including patient examinations, to determine the efficacy of the
12		use of cannabis as a treatment for the patient's medical condition.
13	(4)	Cannabis. – Marijuana as defined in G.S. 90-87(16).
	<u>(4)</u>	· · · · · · · · · · · · · · · · · · ·
14	<u>(5)</u>	Cannabis-infused product. – A product infused with cannabis that is intended
15		for use or consumption other than by inhalation, smoking, or vaping. The term
16 17		includes an edible cannabis product, topical product, ointment, oil, patch,
17	(5)	spray, suppository, or tincture.
18	<u>(6)</u>	Commission. – The Medical Cannabis Production Commission established in
19		G.S. 90-113.122.
20	<u>(7)</u>	Debilitating medical condition. – A diagnosis of one or more of the following
21 22		for which a physician provides a written certification:
22		<u>a.</u> <u>Cancer.</u>
23		<u>b.</u> <u>Epilepsy.</u>
24		<u>c.</u> <u>Positive status for human immunodeficiency virus (HIV).</u>
25		<u>d.</u> <u>Acquired immune deficiency syndrome (AIDS).</u>
23 24 25 26 27		e. Amyotrophic lateral sclerosis (ALS).
27		<u>f.</u> <u>Crohn's disease.</u>
28		 e. Amyotrophic lateral sclerosis (ALS). f. Crohn's disease. g. Sickle cell anemia. h. Parkinson's disease. i. Post-traumatic stress disorder, subject to evidence that an applicant
29		h. Parkinson's disease.
30		i. Post-traumatic stress disorder, subject to evidence that an applicant
31		experienced one or more traumatic events. Acceptable evidence shall
32		include, but is not limited to, proof of military service in an active
33		combat zone, that the person was the victim of a violent or sexual
34		crime, or that the person was a first responder. Details of the trauma
35		shall not be required.
36		
37		 j. Multiple sclerosis. k. Cachexia or wasting syndrome. l. Severe or persistent nausea in a person who is not pregnant that is
38		1. Severe or persistent nausea in a person who is not pregnant that is
39		related to end-of-life or hospice care, or who is bedridden or
40		homebound because of a condition.
41		A
42		
43		G.S. 90-113.116.
44 45		n. Other debilitating medical conditions of the same kind or class as, or
45	(0)	comparable to, those enumerated in this subdivision.
46 47	<u>(8)</u>	<u>Department. – The North Carolina Department of Health and Human</u>
47	(0)	Services.
48	<u>(9)</u>	Designated caregiver. – A person who possesses a valid registry identification
49 50		card issued by the Department authorizing the person to assist a qualifying
50		patient with the medical use of cannabis. A designated caregiver shall be at

1 least 21 years of age unless the person is the parent or legal guardian of each 2 qualifying patient the person assists. 3 Medical cannabis center. – A facility owned and operated by a supplier that (10)4 possesses and dispenses cannabis and cannabis-infused products to registry 5 identification cardholders for human consumption. 6 Medical use of cannabis or medical use. - The acquisition, administration, <u>(11)</u> 7 possession, preparation, transportation, or use of cannabis and 8 cannabis-infused products, or paraphernalia used to administer cannabis 9 products, to treat or alleviate a qualifying patient's debilitating medical 10 condition or symptoms associated with the qualifying patient's debilitating 11 medical condition and includes the transfer of cannabis products from a designated caregiver to a qualifying patient whom the designated caregiver is 12 13 authorized to assist. "Medical use" does not include the extraction of resin 14 from cannabis by solvent extraction other than water, glycerin, propylene 15 glycol, vegetable oil, or food grade ethanol (ethyl alcohol), unless the extraction is done by a processing facility. 16 17 Physician. – A person licensed under Article 1 of Chapter 90 of the General (12)18 Statutes who is in good standing to practice medicine in the State. A physician 19 shall complete a three-hour continuing medical education course on cannabis 20 and an annual one-hour supplemental medical education course thereafter, as 21 approved by the North Carolina Medical Board. Production facility. – A facility owned and operated by a supplier that 22 (13) 23 cultivates, possesses, and produces cannabis and cannabis-infused products. 24 <u>(14)</u> Qualified patient. – A person who has been diagnosed by a physician as 25 having a debilitating medical condition and has received a written 26 certification. 27 <u>(15)</u> Registry identification card. - A document issued by the North Carolina 28 Department of Health and Human Services pursuant to G.S. 90-113.118 that 29 identifies a person as a qualified patient or a designated caregiver. 30 <u>(16)</u> Registry identification cardholder. – A qualified patient or a designated 31 caregiver who holds a valid registry identification card issued by the North 32 Carolina Department of Health and Human Services pursuant to 33 G.S. 90-113.118. 34 Regulated medical cannabis supply system or system. – A system established (17)35 by the North Carolina Department of Health and Human Services pursuant to 36 G.S. 90-113.120 to provide a safe method for producing and distributing 37 cannabis and cannabis-infused products to registry identification cardholders. 38 Supplier. – A person licensed pursuant to G.S. 90-113.120 to supply cannabis (18)39 and cannabis-infused products as authorized by this Article. A supplier 40 cultivates cannabis, owns and operates one or more medical cannabis centers, 41 and owns and operates one or more production facilities as set forth in 42 G.S. 90-113.120. 43 (19)Usable cannabis. – The dried buds and mature female flowers of the plant of 44 the genus Cannabis, and any mixture or preparation thereof, that are 45 appropriate for medical use as provided in this Article. 46 (20)Written certification. – A statement signed by a physician with whom the 47 patient has a bona fide physician-patient relationship indicating the following: 48 In the physician's professional opinion, the patient has a debilitating a. 49 medical condition.

1		<u>b.</u>	In the physician's professional opinion, the potential health benefits of
2			the medical use of cannabis would likely outweigh the health risk for
3			the patient.
4		<u>c.</u>	The delivery method of the cannabis.
5	" <u>§ 90-113.116. N</u>	<u> 1edical</u>	Cannabis Advisory Board; membership; terms; meetings; quorum;
6	<u>exper</u>		
7		•	ard Established. – The Medical Cannabis Advisory Board is established
8	·		nembers as follows:
9	<u>(1)</u>	The C	Governor shall appoint members to the Advisory Board as follows:
10		<u>a.</u>	A physician specializing in pain management.
11		<u>b.</u>	A general physician.
12		<u>c.</u>	A physician specializing in osteopathic medicine.
13 14		<u>d.</u>	A physician who is board-certified to practice addiction medicine in
15		0	North Carolina. A research scientist with expertise in the field of cannabinoid
16		<u>e.</u>	medicine.
17		<u>f.</u>	A licensed pharmacist.
18		<u>r.</u> g.	A registry identification cardholder or, for an appointment made
19		= -	before registry identification cards are issued, one person with a
20			debilitating medical condition who intends to use cannabis.
21		<u>h.</u>	A parent of a minor qualified patient or, for an appointment made
22		_	before registry identification cards are issued, one parent of a minor
23			with a debilitating medical condition who intends to use cannabis.
24		<u>i.</u>	A representative of a supplier or, for an appointment made before
25			suppliers are licensed, a prospective supplier.
26	<u>(2)</u>		members appointed by the General Assembly upon recommendation of
27			beaker of the House of Representatives in accordance with G.S. 120-121.
28	<u>(3)</u>		members appointed by the General Assembly upon recommendation of
29	(1) T		resident Pro Tempore of the Senate in accordance with G.S. 120-121.
30			embers of the Advisory Board shall serve a four-year term, beginning
31			ear of appointment, and may be reappointed to a second four-year term.
32			members of the Advisory Board shall elect a chair. The chair shall serve
33 34	a two-year term a (d) Meeti		The Advisory Board shall meet at least two times per year for the purpose
35		_	add debilitating medical conditions.
36	• •		Advisory Board shall have the power to approve adding a debilitating
37			najority vote of the members present and voting.
38			even members of the Advisory Board shall constitute a quorum for the
39	transaction of bu		
40			The members of the Advisory Board shall receive per diem and necessary
41	travel and subsis	tence ex	spenses in accordance with the provisions of G.S. 138-5.
42	" <u>§ 90-113.118.</u>	Regis	stry identification cards for qualified patients and designated
43	careg	<u>ivers.</u>	
44			Issuance, and Expiration of Registry Identification Cards The
45	-		or renew a registry identification card to the following individuals:
46	<u>(1)</u>		individual who applies to the Department on forms prescribed by the
47			rtment demonstrating that the individual is a qualified patient with a
48			tating medical condition for which a physician has issued a written
49	(2)		cation.
50	<u>(2)</u>		ndividual who is at least 21 years of age who has (i) been named as a
51		uesigi	nated caregiver in a registry identification card application submitted by

a qualified patient and (ii) agreed to serve as that qualified patient's designated caregiver. The Department may issue a registry identification card to a maximum of two designated caregivers named in a qualified patient's approved application.

The Department shall issue a registry identification card to an applicant within 14 business days after approving an application or renewal. The initial or renewal registry identification card expires one year after the date of issuance.

- (b) Qualified Patients Under Age 18. The Department may not issue or renew a registry identification card to a qualified patient under 18 years of age unless each of the following criteria is met:
 - (1) The qualified patient's physician has explained the potential risks and benefits of the medical use of cannabis to the qualified patient and to a parent, guardian, or person having legal custody of the qualified patient.
 - (2) The qualified patient's physician restricts the qualified patient's use of cannabis to a noninhalation consumption method, and the qualified patient and the qualified patient's designated caregivers agree to comply with this restriction.
 - (3) A parent, guardian, or person having legal custody of the qualified patient consents in writing to (i) allow the qualified patient's medical use of cannabis, (ii) serve as one of the qualified patient's designated caregivers, and (iii) control the acquisition of the cannabis, the dosage, and the frequency of the medical use of cannabis by the qualified patient.
- (c) Review of Applications. The Department shall verify the information contained in a registry identification card application or renewal application submitted pursuant to this section and shall approve or deny an application or renewal application within 45 days after receipt.
- (d) Denials and Appeals. The Department may deny a registry identification card application or renewal application only if the applicant fails to provide the information required pursuant to this section or if the Department determines that the application or renewal application contains false information. Denials may be appealed by filing a contested case petition under Article 3 of Chapter 150B of the General Statutes. Article 4 of Chapter 150B of the General Statutes governs judicial review of an administrative decision made under this section.
- (e) Registry Identification Card Information. Each registry identification card issued by the Department shall be printed with tamper-resistant technology and shall contain at least all of the following information:
 - (1) The name of the cardholder.
 - (2) The address of the cardholder.
 - (3) The cardholder's date of birth.
 - (4) A designation of whether the cardholder is a designated caregiver or qualifying patient.
 - (5) The date of issuance and expiration date of the registry identification card.
 - (6) A random alphanumeric identification number that is unique to the cardholder.
 - (7) If the cardholder is a designated caregiver, the random alphanumeric identification number of the qualifying patients that the designated caregiver is authorized to assist.
 - (8) A photograph of the cardholder.
 - (9) The delivery method of the cannabis.
- (f) Notification of Changes. Individuals issued registry identification cards are subject to all of the following:
 - (1) A qualified patient who has been issued a registry identification card shall notify the Department of any change in the qualified patient's name, address,

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

- or designated caregiver and submit a fifty dollar (\$50.00) fee to the 2 Department within 15 days after the change occurs. A qualified patient who 3 fails to notify the Department of any of these changes within the specified 4 time frame commits an infraction and is subject to a fine not to exceed one 5 hundred dollars (\$100.00). 6
 - A designated caregiver shall notify the Department of any change in name or <u>(2)</u> address and submit a fifty dollar (\$50.00) fee to the Department within 15 days after the change occurs. A designated caregiver who fails to notify the Department of any of these changes within the specified time frame commits an infraction and is subject to a fine not to exceed one hundred dollars (\$100.00).
 - When a qualified patient or designated caregiver notifies the Department of (3) any change, as required by this subsection, the Department shall issue the qualified patient and each designated caregiver a new registry identification card within 10 days after receiving the updated information and the fifty dollar (\$50.00) fee.
 - When a qualified patient who possesses a registry identification card notifies (4) the Department of a change in designated caregiver, the Department shall notify the designated caregiver of record of the change within 15 days after receiving notification of the change. The protections afforded under this Article to the designated caregiver of record shall expire 30 days after the designated caregiver of record is notified by the Department of the change in designated caregiver.
 - <u>(5)</u> If a qualified patient or a designated caregiver loses a registry identification card, the cardholder shall notify the Department within 15 days after losing the card. The notification shall include a fifty dollar (\$50.00) replacement fee for a new card. Within five days after receiving notification of a lost registry identification card, the Department shall issue the cardholder a new registry identification card with a new random identification number.
 - Suspensions or Revocations. If the Department determines that a qualified patient or designated caregiver has violated any provision of this Article, the Department shall suspend or revoke the qualified patient's or designated caregiver's registry identification card. Suspensions or revocations may be appealed by filing a contested case petition under Article 3 of Chapter 150B of the General Statutes.
 - Confidential Medical Cannabis Registry Database. The Department shall create a secure, confidential, electronic medical cannabis registry database of all qualified patients and designated caregivers to whom the Department has issued registry identification cards. Law enforcement agencies may contact the Department to confirm registry identification cardholders. The Department shall monitor the medical cannabis registry database and in the event that the Department finds patterns of written certifications that are unusual, the Department shall inform the Attorney General's Office of its findings. The Office of the Attorney General shall review the Department's findings to determine if the findings should be reported to the State Bureau of Investigation and the appropriate sheriff for investigation of possible violations of State or federal law. The database shall consist of at least the following information:
 - The name and address of the registry identification cardholder. **(1)**
 - (2) The name, address, and hospital affiliation of the physician who issued the written certification of the qualified patient's debilitating condition.
 - A photograph of the registry identification cardholder. (3)
 - Confidential Nature of Information Collected by Department. Applications and supporting information submitted by qualified patients, including information regarding their designated caregivers and physicians, individual names, and other identifying information in the

medical cannabis registry database, are confidential, exempt from the provisions of Chapter 132 of the General Statutes, and are not subject to disclosure, except to authorized employees of the Department as necessary to perform official duties of the Department and law enforcement agencies as allowed in subsection (h) of this section.

Penalty for Confidentiality Breaches. – Any person, including an employee or official

- 5 6 of the Department or another State agency or local government, who breaches the confidentiality 7 8 9
 - of information obtained pursuant to this section is guilty of a Class 2 misdemeanor; however, any fine imposed for a violation under this subsection shall not exceed one thousand dollars (\$1,000).Reports of Falsified or Fraudulent Application Information to Law Enforcement (k) Personnel. – Nothing in this section shall be construed to prevent Department employees from
- 11 12 13

10

- notifying law enforcement personnel about falsified or fraudulent information submitted to the Department by any individual in support of an application for a registry identification card. Rules. – Not later than 270 days after the effective date of this act, the North Carolina Medical Care Commission shall adopt rules to implement the provisions of this section. The rules shall establish requirements for the issuance of registry identification cards to qualified patients
- 16 17 18

14

15

The method of demonstrating written certification, as defined in <u>(1)</u> G.S. 90-113.114.

19 20

(2) The amount of the initial or renewal application fee, which shall not exceed fifty dollars (\$50.00) per application or renewal application.

21 22 23

The name, address, and date of birth of the qualified patient. <u>(3)</u>

24

The name, address, and telephone number of the qualified patient's physician. <u>(4)</u> (5) The name, address, and date of birth of each of the qualified patient's designated caregivers, if any.

25 26

27

"§ 90-113.120. Regulated medical cannabis supply system.

28 29

Definitions. – The following definitions apply in this section: (a)

and designated caregivers, which shall include at least all of the following:

30 31 <u>(1)</u> Nonresident business. – An entity that has not been required to file an income or franchise tax return with the State for three years prior to filing an initial application for a medical cannabis supplier license that meets one or more of the following conditions:

32

Is a nonresident entity. <u>a.</u>

33

Is a nonresident individual who owns an unincorporated business as a <u>b.</u> sole proprietor.

34 35

Nonresident entity. – Defined in G.S. 105-163.1. (2)

36 37

Nonresident individual. – Defined in G.S. 105-153.3. (3) Medical Cannabis Supply System; Funding. – Not later than 270 days after the

43

44

G.S. 90-113.122 shall establish a medical cannabis supply system that authorizes suppliers to produce cannabis and cannabis-infused products in licensed cannabis products facilities and distribute them through medical cannabis centers. In establishing the medical cannabis supply system, the Commission shall (i) provide a safe, regulated supply of cannabis appropriate for medical use by qualified registry identification cardholders issued under G.S. 90-113.118, (ii) ensure statewide access to safe and affordable cannabis to registry identification cardholders, (iii) establish a system that is well regulated, includes a seed-to-sale tracking system, and is

effective date of this act, the Medical Cannabis Production Commission established in

- 45 46
 - financially viable for suppliers to ensure the highest quality cannabis and cannabis-infused
- 47 products for patients, and (iv) generate sufficient revenue for the Commission to oversee and for 48
 - the Department to maintain and operate the system. The General Assembly may appropriate funds for the initial development and implementation of the medical cannabis supply system, but
- 49 50
 - neither the Department nor the Commission shall use any appropriations from the General Fund

1 to operate the system. The intent of the General Assembly is that the system shall be funded 2 solely by the fees authorized in this section. 3 Medical Cannabis Supplier License. – (c) 4 No person shall do any of the following without first obtaining a medical (1) 5 cannabis supplier license from the Commission: 6 Grow, cultivate, produce, or sell cannabis or cannabis-infused a. 7 products. 8 Operate a business to produce cannabis or cannabis-infused products. <u>b.</u> 9 Establish or operate a medical cannabis center for the sale of cannabis, <u>c.</u> 10 cannabis-infused products, and paraphernalia relating to the 11 administration of cannabis to qualified patients and designated caregivers who hold valid registry identification cards. 12 13 An applicant for a license under this subsection shall submit the required **(2)** 14 information on application forms provided by the Department. The application form shall require at least all of the following: 15 16 The applicant's name and any legal names the applicant will use for a. 17 facilities where the applicant will produce cannabis and for each medical cannabis center and production facility the applicant proposes 18 19 to operate. 20 The address of each property, location, or premises the applicant will <u>b.</u> 21 use to produce cannabis, of each production facility the applicant will 22 use to process cannabis or produce cannabis-infused products, and of 23 each medical cannabis center the applicant will use to dispense or 24 distribute cannabis. 25 Documentation demonstrating that the applicant possesses: <u>c.</u> 26 Requisite expertise in controlled environment agriculture and 1. 27 at least five years of experience in cultivation, production, 28 extraction, product development, quality control, and 29 inventory management of medical cannabis in a state-licensed 30 medical or adult use cannabis operation meeting standards that 31 the Commission shall specify by rule. 32 Significant technical and technological ability to cultivate, <u>2.</u> 33 produce, and distribute medical cannabis in a manner that 34 meets industry standards for production consistency and safe 35 handling. 36 Relevant experience in securing cannabis production, testing, 3. 37 resources, transportation, and personnel to operate as a safe and 38 secure supplier in compliance with all state regulations in 39 which the applicant has prior experience. 40 Proposed operating procedures for each production facility, medical <u>d.</u> 41 cannabis center, and component of the applicant's proposed medical 42 cannabis supply system, including record keeping and security 43 requirements as the Commission shall specify by rule. 44 The name, address, and date of birth of each principal officer and <u>e.</u> 45 board member of the supplier. The name, address, and date of birth of each employee of the supplier. 46 f. 47 For first-year licensees, a nonrefundable license fee in the amount of g. 48 fifty thousand dollars (\$50,000) plus five thousand dollars (\$5,000) for 49 each production facility or medical cannabis center the applicant 50 proposes to operate under the license.

		ory Of t	tor in Caronna	Session 2021		
1		<u>h.</u>	For licensees seeking license renewal, a non	refundable renewal fee in		
2			an amount not less than ten thousand do	dlars (\$10,000) plus one		
3			thousand dollars (\$1,000) for each production			
4			cannabis center the licensee operates under			
5			rules adopted by the Commission pursuan	-		
6			annual audited financial statements audi			
7			certified public accountant.	ned by an independent		
8		<u>i.</u>	Proof the applicant has been a State resident	for at least two years and		
9		<u>1.</u>	will be the majority owner of each med			
10			•	•		
10			production facility the applicant proposes			
			may include nonresident partners with dem			
12			operation experience in the cultivation, produ	_		
13			development, quality control, and inventory			
14			products in a state-licensed medical or adu			
15			and shall provide proof of state residency for	or any nonresident partner		
16			of the applicant.			
17		<u>j.</u>	The name, address, and date of birth of any			
18			than five percent (5%) of the medical canna	bis center and production		
19			<u>facility the licensee operates.</u>			
20		<u>k.</u>	Proof in a manner and amount as the Commi			
21			that the applicant has sufficient liquid and n	onliquid assets to operate		
22			as a supplier for two years as a part of the	medical cannabis supply		
23			system established by this Article.			
24		<u>l.</u>	Any other information the Department cons	siders necessary to ensure		
25			compliance with the terms of this Article.	-		
26	<u>(3)</u>	Unles	s suspended or revoked, a medical cannabis su	upplier license is valid for		
27		a peri	od not to exceed 12 months from the date of is	ssuance.		
28	<u>(4)</u>	A lice	nsee shall apply for renewal, as necessary, at	least 30 days prior to the		
29		expira	tion of a current license.	v -2		
30	<u>(5)</u>	No lat	er than 30 days after issuing or renewing a lice	ense under this subsection,		
31		the D	epartment shall issue a supplier registry id	entification card to each		
32			or and employee listed on the application or re			
33			vo hundred fifty dollar (\$250.00) fee per cardl	_		
34	<u>(6)</u>	A lice	ensee shall notify the Department of any ch	hange in the information		
35			tted on the license application or renewal form			
36		chang	* *			
37	<u>(7)</u>		ecords of a medical cannabis center operated b	ov a supplier are subject to		
38	<u> </u>		me restrictions imposed on pharmacy records p			
39			0-85.36 applies to each medical cannabis cent	-		
40			ted under Article 4A of Chapter 90 of the Ger			
41	<u>(8)</u>		Department shall issue a medical cannabis pro			
42	(0)		er for each production facility approved und			
43			be posted conspicuously at each production factors			
4 3	<u>(9)</u>		plier is required to grow cannabis in a contro			
45	<u>(9)</u>		where cannabis is grown shall not be open to			
43 46				_		
	(d) Doufo		cess controls and restrictions as the Commiss			
47 48			Requirements. – A licensee must begin cultive modified gamphic gamplion licensee and be			
48		_	a medical cannabis supplier license and be	-		
49 50		-	s in medical cannabis centers within 180 days	_		
50			ons for Licensure. – The Commission sh	nan not issue a license		
51	authorized by this section to any of the following persons:					

2

3

4

5

6

7

8

9

10

11

12 13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

- (1) A person who has not paid the appropriate license or license renewal fee.
 - (2) An individual who is less than 21 years of age.
 - (3) A person who has served a sentence for any of the following felonies in the five years immediately preceding the date of license application: any Class A through E felony; any felony that includes assault as an essential element of the offense; any felony under Article 14 (Burglary and Other Housebreakings) of Chapter 14 of the General Statutes; any felony under Article 16 (Larceny), Article 16A (Organized Retail Theft), Article 17 (Robbery), Article 18 (Embezzlement), Article 19 (False Pretenses and Cheats), Article 19A (Obtaining Property or Services by False or Fraudulent Use of Credit Device or Other Means), Article 19B (Financial Transaction Card Crime Act), or Article 19C (Financial Identity Theft) of Chapter 14 of the General Statutes.
 - (4) A person (or, with respect to a person who is not an individual, an owner, director, or employee of the person) who at any time has been convicted of a felony violation for manufacturing, selling, delivering, or possessing with intent to manufacture, sell, deliver, or possess a Schedule I or II controlled substance, in violation of G.S. 90-95(b)(1).
 - (5) Except as otherwise provided in this subdivision, a person who has not been a resident of North Carolina for at least two years prior to the date of the license application, unless that person is a minority partner of a State resident who is the majority owner of the applicant. With respect to a person who is not an individual, a person that is a nonresident business.
- Criminal History Record Check. In order to ensure compliance with this section, the Department shall conduct a criminal history record check of any person whose name is submitted on an application as an owner, director, or an employee of the supplier. When requested by the Department, the North Carolina Department of Public Safety may provide to the Department a person's criminal history from the State Repository of Criminal Histories. Such requests shall not be due to a person's age, sex, race, color, national origin, religion, creed, political affiliation, or handicapping condition as defined in G.S. 168A-3. For requests for a State criminal history record check only, the Department shall provide to the Department of Public Safety a form consenting to the check signed by the person to be checked and any additional information required by the Department of Public Safety. National criminal record checks are authorized for applicants who have not resided in the State of North Carolina during the past five years. For national checks, the Department shall provide to the North Carolina Department of Public Safety the fingerprints of the person to be checked, any additional information required by the Department of Public Safety, and a form signed by the person to be checked consenting to the check of the criminal record and to the use of fingerprints and other identifying information required by the State or National Repositories. The fingerprints of the individual shall be forwarded to the State Bureau of Investigation for a search of the State criminal history record file and the State Bureau of Investigation shall forward a set of fingerprints to the Federal Bureau of Investigation for a national criminal history record check. The Department of Health and Human Services shall keep all information pursuant to this section confidential. The Department of Public Safety shall charge a reasonable fee for conducting the checks of the criminal history records authorized by this section. All releases of criminal history information to the Department shall be subject to, and in compliance with, rules governing the dissemination of criminal history record checks as adopted by the North Carolina Department of Public Safety. All of the information either department receives through the checking of the criminal history is privileged information and for the exclusive use of that department.
- (g) Restrictions on Sales and Supply. A person licensed as a supplier under this section is subject to the following sales and supply restrictions:

- (1) The supplier may sell cannabis and cannabis-infused products only through the medical cannabis center that the supplier is licensed to operate under this section. A medical cannabis center shall not sell cannabis, cannabis-infused products, or paraphernalia relating to the administration of cannabis to any person other than a qualified patient, designated caregiver, or except as provided in subdivision (3) of this subsection. A medical cannabis center shall not sell cannabis or cannabis-infused products in an amount that exceeds an adequate supply to any qualified patient or designated caregiver.
- (2) The supplier may sell only cannabis grown by the supplier at the production facilities approved under this section. Except as provided in subdivision (3) of this subsection, the supplier shall not sell cannabis, cannabis plants, cannabis seeds, or cultivation equipment to any other person other than through the medical cannabis center that the supplier is licensed to operate.
- (3) The supplier may sell cannabis or cannabis-infused products for resale to another licensed supplier.
- (h) Exemption from Criminal Laws. A supplier is exempt from the criminal laws of this State for possession, production, delivery, or transportation of cannabis, or aiding and abetting another in the possession, production, delivery, or transportation of cannabis, or any other criminal offense in which possession, production, delivery, or transportation of cannabis is an element if the individual is in compliance with this Article and rules adopted under this Article.
- (i) Loss of Exemption from Criminal Laws. A person who is not a qualified patient or a designated caregiver but who is otherwise authorized to possess, produce, deliver, or transport cannabis for medical use pursuant to this Article ceases to be exempt as provided in subsection (h) of this section upon committing any of the following acts:
 - (1) Driving while impaired in violation of G.S. 20-138.1, 20-138.2, or 20-138.5.
 - (2) Delivering cannabis to any individual who the person knows or has reason to know is not a qualified patient or designated caregiver who holds a valid registry identification card issued under G.S. 90-113.118, or a supplier who holds a license under this section.
 - (3) Manufacturing or distributing cannabis at an address not registered with the Department.
 - (4) Failing to report transfer of cannabis authorized under this section to the Department.
 - (j) Reporting and Monthly Fees.
 - (1) Each supplier licensed under this section shall submit quarterly reports to the Department on all financial transactions, including, but not limited to, production, sales and purchases of cannabis and cannabis-infused products, and transfers of cannabis and cannabis-infused products for no consideration with respect to each medical cannabis center and production facility operated by the supplier.
 - (2) Each supplier licensed under this section shall pay to the Department a monthly fee equal to ten percent (10%) of the gross revenue derived from the sale of cannabis and cannabis-infused products at all medical cannabis centers operated by the supplier.
 - (3) Nothing in this subsection shall be construed to exempt persons licensed under this section from the reporting or remittance of sales tax for any transaction upon which a sales tax may be levied.
- (k) Duty to Update. In order to continue to hold a license under this Article, a medical cannabis licensee shall notify the Commission of any change in criminal history of any person required to be evaluated by the Department under this section. The Commission may reevaluate the licensee's eligibility for a license based on the notification and may modify or revoke the

- 1 <u>license or require issuance of a new license with appropriate terms to exclude disqualifying persons.</u>
 - (*l*) Self-Supporting Requirement. The system revenues from license fees and monthly gross revenue fees are appropriated to the Commission to fund in the following order of priority:
 - (1) Costs associated with establishing and operating the regulated medical cannabis supply system established under this section.
 - (2) The registry system established under G.S. 90-113.118.
 - (3) The North Carolina Cannabis Research Program established under G.S. 90-113.132, limited to an amount of funding to be determined by the Commission.
 - (m) Use of Excess Revenues. Any revenues remaining at the end of a fiscal year after the Commission fully funds the priorities set forth in subsection (*l*) of this section shall be transferred at the beginning of the subsequent fiscal year to the General Fund.
 - (n) <u>Inspection. The Department shall perform annual inspections of the premises of any person licensed under this section, including any production facility or medical cannabis center.</u>
 - (o) Security Measures and Inspection.
 - (1) Suppliers shall implement appropriate security measures in accordance with rules adopted by the Commission, which shall be developed by the Commission after consulting with and receiving input from the North Carolina State Bureau of Investigation, designed to deter and prevent the theft of cannabis and cannabis-infused products and unauthorized entrance into areas containing cannabis or cannabis-infused products.
 - All production facilities shall conduct cultivation, harvesting, processing, and packaging of cannabis and cannabis products in a controlled, secure facility at a physical address provided to the Commission during the medical cannabis supplier license application process. A production facility may only be accessed by a supplier or a supplier's employee or agent, authorized Department personnel, law enforcement personnel, emergency personnel, and adults who are 21 years of age and older who are accompanied by a supplier or supplier's agents or principals.
 - All production facilities and medical cannabis centers owned and operated by a supplier are subject to random inspection by the Department, and the North Carolina State Bureau of Investigation in accordance with rules adopted by the Commission, which shall be developed by the Commission after consulting with and receiving input from the North Carolina State Bureau of Investigation.
 - (p) <u>Limitation. The Commission shall issue no more than 10 supplier licenses pursuant to this section. In awarding the licenses, the Commission shall require each supplier own and operate no more than four medical cannabis centers. Of the medical cannabis centers operated by each supplier, at least two shall be located in Tier 1 counties.</u>
 - (q) Administrative and Judicial Review. Articles 3 and 4 of Chapter 150B of the General Statutes govern administrative and judicial review of an administrative decision made under this section.

"§ 90-113.121. Violations; penalties; and enhanced sentence for trafficking related to medical cannabis.

- (a) Any person who manufactures, sells, delivers, or possesses with intent to manufacture, sell, or deliver cannabis in violation of this Article at a medical cannabis center or production facility shall be punished as a Class G felon.
- (b) Any person who creates, sells, delivers, or possesses with intent to sell or deliver counterfeit cannabis in violation of this Article at a medical cannabis center or production facility shall be punished as a Class H felon.

- (c) Any person who possesses an amount of cannabis up to 1 1/2 ounces in violation of this Article, at a medical cannabis center or production facility, shall be deemed guilty of a Class A1 misdemeanor.
- (d) Any person who possesses an amount of cannabis that exceeds 1 1/2 ounces in violation of this Article, at a medical cannabis center or production facility, shall be punished as a Class H felon.
- (e) Any person that provides the Department with false or misleading information in relation to a registry identification card or license shall be deemed guilty of a Class 1 misdemeanor.
- (f) Any person who has been issued a valid registry identification card who is found to be in possession of cannabis in violation of this Article shall be punished as a Class I felon.
- (g) If a person is convicted of a violation of G.S. 90-95(h)(1), and it is found that the offense was committed at a medical cannabis center or production facility or with cannabis from a medical cannabis center or production facility, then the person shall be sentenced at a felony class level one class higher than the principal felony for which the person was convicted, and an additional 12 months will be added to the mandatory minimum sentence. No defendant sentenced pursuant to this section shall be sentenced at a level higher than a Class C felony. An indictment or information for the felony shall allege in that indictment or information the facts that qualify the offense for an enhancement under this section. One pleading is sufficient for all felonies that are tried at a single trial.
- (h) These penalties may be imposed in addition to any other penalties provided by law. "§ 90-113.122. Medical Cannabis Production Commission.
- (a) Commission Established. The Medical Cannabis Production Commission is established and shall consist of nine members as follows:
 - (1) The Governor shall appoint members to the Medical Cannabis Production Commission as follows:
 - a. A qualified patient representative.
 - b. Two industry representatives, subject to the limitation that, although the industry representatives may participate in assisting with the process of adopting rules, the industry representatives must not participate in the license selection process if the industry representatives have applied for or have an affiliation with a medical cannabis supplier license applicant through family or business.
 - (2) The Secretary of the Department, or designee.
 - (3) The Director of the North Carolina State Bureau of Investigation, or designee.
 - (4) A sheriff designated by the North Carolina Sheriffs' Association.
 - (5) A member of the North Carolina Medical Board.
 - (6) A member appointed by the General Assembly upon recommendation of the Speaker of the House of Representatives in accordance with G.S. 120-121.
 - (7) A member appointed by the General Assembly upon recommendation of the President Pro Tempore of the Senate in accordance with G.S. 120-121.
- (b) Terms. Members of the Commission shall serve terms of four years, beginning effective July 1 of the year of appointment, and may be reappointed to a second four-year term. The terms of members designated by subdivisions (a)(1), (a)(2), and (a)(4) of this section shall expire on June 30 of any year evenly divisible by four. The terms of the remaining members shall expire on June 30 of any year that follows by two years a year evenly divisible by four.
- (c) Chair. The members of the Commission shall elect a chair. The chair shall serve a two-year term and may be reelected.
- (d) Vacancies. Any appointment to fill a vacancy on the Commission created by the resignation, dismissal, death, or disability of a member shall be made by the original appointing authority and shall be for the balance of the unexpired term.

- (e) Removal. The appointing authority shall have the power to remove any member of the Commission appointed by that authority from office for misfeasance, malfeasance, or nonfeasance.
- (f) Expenses. The members of the Commission shall receive per diem and necessary travel and subsistence expenses in accordance with the provisions of G.S. 138-5.
- (g) Quorum. Five members of the Commission shall constitute a quorum for the transaction of business.
- (h) <u>Licensing Power. The Commission shall have the power to approve applications for medical cannabis supplier licenses upon recommendation of the Department by a majority vote of the members present and voting. The Department shall evaluate the applications in accordance with G.S. 90-113.120 and submit a list of 20 applicants to the Commission. The Commission shall approve 10 licenses from the list by a majority vote of the members present and voting.</u>
- (i) <u>License Suspension or Revocation.</u> The Commission may suspend or revoke a medical cannabis supplier license if the Commission determines that the licensee is not in substantial compliance with this Chapter or with rules adopted by the Commission under subsection (j) of this section. The Department shall notify a licensee at least 14 days in advance of a proposed suspension or revocation, including the reasons for the suspension or revocation and any possible remedial options available to the licensee. The Commission has the power to administer oaths and issue subpoenas to require the presence of persons and the production of papers, books, and records necessary to conduct a suspension or revocation hearing. The suspension or revocation may be appealed by filing a contested case petition under Article 3 of Chapter 150B of the General Statutes.
- (j) All administrative support and other services required by the Commission shall be provided by the Department.
- (k) Rules. Not later than 270 days after the effective date of this act, the Commission, in consultation with the North Carolina Medical Care Commission, shall adopt rules to implement the provisions of this section and G.S. 90-113.120. The rules shall do all of the following:
 - (1) Establish qualifications and requirements for licensure of suppliers, for the production of cannabis by a supplier, and for the proper regulation of medical cannabis centers and production facilities operated by suppliers.
 - Ensure the equitable distribution of medical cannabis centers throughout the State in order for registry identification cardholders to access an adequate supply of cannabis and cannabis-infused products, while preventing an overconcentration of medical cannabis centers in any one area.
 - (3) Establish civil penalties for minor violations of the requirements of this Chapter and rules adopted under the authority provided in this subsection.

"§ 90-113.124. Testing of cannabis and cannabis-infused products.

- (a) The Department shall establish standards for and shall license up to five independent testing laboratories to test cannabis and cannabis-infused products that are to be sold in the State. An independent testing laboratory shall analyze a representative sample of all cannabis or cannabis-infused products before the sale or transfer to a medical cannabis center by a production facility. An independent testing laboratory shall report the results of all testing required by the Department to the Department.
- (b) An independent testing laboratory shall be responsible for selecting, picking up, and testing product samples.
 - (c) The Department shall adopt rules to establish, at a minimum, the following:
 - (1) Standards for testing cannabis and cannabis products, including specifying prohibited concentrations of heavy metals, pesticides, microbes, and other contaminants that are injurious to human health.

General Assembly Of North Carolina 1 Standards for independent testing laboratories, including requirements for (2) 2 equipment and qualifications for personnel. 3 Standards and requirements necessary for an independent testing laboratory <u>(3)</u> 4 to be licensed. 5 Remedial actions to be taken if the representative sample does not meet the <u>(4)</u> 6 standards established by the Department. 7 A fee schedule for independent testing laboratories. (5) 8 "§ 90-113.126. Advertising and packaging of cannabis and cannabis-infused products. 9 Definitions. – The following definitions apply in this section: (a) 10 Child-resistant packaging. – A package that is designed or constructed to be <u>(1)</u> 11 significantly difficult for children under 5 years of age to open and not difficult 12 for normal adults to use properly, substantially similar to those defined by 16 13 C.F.R. § 1700.20 (1995), opaque so that the packaging does not allow the 14 product to be seen without opening the packaging material, and resealable for 15 any product intended for more than a single use or containing multiple 16 servings. 17 Exit packaging. – A sealed, child-resistant packaging receptacle into which (2) pre-packaged cannabis products are placed at the retail point of sale at a 18 19 medical cannabis center. 20 The production facility or medical cannabis center logo, advertising, and signage shall (b) 21 be tasteful, respectful, and medically focused and shall not appeal to minors or contain 22 cartoon-like figures or attempts at humor. 23 Suppliers are prohibited from using marijuana leaves or slang for cannabis or 24 cannabis-infused products in or on their signs, logos, packaging, or structures. Suppliers may not 25 use neon-colored signage, logos, or packaging or neon-colored signage or logos on structures. 26 The supplier shall submit any logo or sign for review to the Department in accordance with 27 Department rules. 28 (d) All production facilities and medical cannabis centers owned and operated by a 29 supplier shall maintain a discreet, professional appearance that is compatible with existing 30 commercial structures or land uses within the immediate area, including requirements to maintain 31 the production facility or medical cannabis center in a manner to prevent blight, deterioration, 32 diminishment, or impairment of property values within the vicinity. 33 Suppliers shall safely package and accurately label cannabis or cannabis-infused 34 products. All items sold at a medical cannabis center shall be properly labeled and contained in 35 child-resistant packaging. Labels shall not include strain names but may include cannabinoid and 36 terpene profiles for identification. Each label shall comply with State laws and rules and, at a 37 minimum, shall include: 38 The name of the medical cannabis center. <u>(1)</u> 39 (2) The percentage of tetrahydrocannabinol and the percentage of cannabidiol 40 within a profile tolerance range of ten percent (10%). For edible cannabis 41 products, the cannabinoid profile should be listed by milligrams per serving. 42 The name of the production facility. (3) A conspicuous statement printed in all capital letters and in a color that 43 (4) 44 provides a clear contrast to the background that reads, "NOT FOR RESALE. 45 FOR MEDICAL USE ONLY. KEEP OUT OF THE REACH OF CHILDREN 46 AND ANIMALS.". 47 The length of time it typically takes for the product to take effect. <u>(5)</u>

For edible cannabis-infused products, the disclosure of ingredients, possible

allergens, nutritional fact panel, and a standard symbol indicating that the

product contains cannabis.

(6)

48

49

- (f) All cannabis products purchased in medical cannabis centers shall be placed in child-resistant exit packaging before leaving the medical cannabis center.
 - (g) The Department shall adopt rules to do, at a minimum, all of the following:
 - (1) Establish requirements and procedures for the safe, appropriate, and accurate packaging and labeling of cannabis and cannabis-infused products for human consumption, including prohibiting the use of any images designed or likely to appeal to minors, including cartoons, toys, animals, or children, any other likeness to images, characters, or phrases that are popularly used to advertise to children, or any imitation of candy packaging or labeling.
 - (2) Establish requirements to ensure that cannabis and cannabis-infused products for human consumption are designed, marketed, and packaged in a manner that is appropriate for a medicinal product and that does not resemble commercially sold candies or other food that is typically marketed to children.
 - (3) Establish restrictions on the forms and appearance of edible cannabis-infused products in order to reduce their appeal to minors, including prohibiting edible cannabis products in the shapes of cartoons, toys, animals, or people.

"§ 90-113.128. Disposal of cannabis.

- (a) All production center cannabis by-product, cannabis scrap, and harvested cannabis not intended for distribution to a medical cannabis center or independent testing laboratory shall be destroyed and disposed of in accordance with Department rules. Documentation of destruction and disposal shall be retained by the production center for a period of not less than one year. The production center shall maintain a record of the date of destruction and the amount destroyed.
- (b) A medical cannabis center shall destroy all cannabis and cannabis-infused products that are not sold to qualifying patients or designated caregivers in accordance with Department rules. The medical cannabis center shall retain documentation of the destruction and disposal for a period of not less than one year. The medical cannabis center shall maintain a record of the date of destruction and the amount destroyed.
- (c) A medical cannabis center shall destroy all unused cannabis products that are returned to the medical cannabis center by a former qualifying patient who no longer qualifies for the use of medical cannabis or the former qualifying patient's caregiver.

"§ 90-113.130. North Carolina medical cannabis verification system.

- (a) <u>Verification System. The Department shall establish a secure web-based verification system. The verification system shall allow authorized Department personnel, State and local law enforcement personnel, and medical cannabis centers to enter a registry identification card number to determine whether the number corresponds with a current, valid registry identification card. For the purposes of this subsection, the system may disclose only:</u>
 - (1) Whether the registry identification card is valid.
 - (2) The name, address, and date of birth of the cardholder.
 - (3) A photograph of the cardholder, if required by Department rules.
 - (4) Whether the cardholder is a qualifying patient or a designated caregiver.
 - (5) The registry identification card number of any associated qualifying patients or designated caregivers.
 - Only if accessed by a medical cannabis center employee or authorized Department personnel, the amount of cannabis and cannabis-infused products dispensed in the past 30 days.
 - (7) The delivery method of the cannabis.
- (b) Verification System Access. No person or entity may have access to information contained in the Department's verification system, except for an authorized employee of the Department in the course of official duties or a State or local law enforcement officer in the course of official duties related to a person who claims to be a qualifying patient, designated caregiver, supplier, or supplier agent engaged in conduct authorized in this Article.

- (c) Requirement to Check. Before cannabis or cannabis-infused products may be dispensed to a registry identification cardholder, a medical cannabis center employee shall access the verification system and determine that:
- 4 5
- (1) The registry identification card presented at the medical cannabis center is valid.

 (2) Each person presenting a registry identification card is the person identified on the registry identification card presented to the medical cannabis center employee.

(3) The amount to be dispensed would not cause a qualifying patient, directly or via the qualifying patient's designated caregiver, to exceed the limit on obtaining no more than an adequate supply of cannabis or cannabis-infused products during any 30-day period.

(4) The cannabis to be dispensed complies with the delivery method.

 (5) After making the determinations required in subdivision (3) of this subsection, but before dispensing cannabis or cannabis-infused products to a registry identification cardholder, a medical cannabis center employee shall enter the following information in the verification system:

a. How much cannabis or cannabis-infused product is to be dispensed to the registry identification cardholder.

 b. Whether the cannabis or cannabis-infused product is to be dispensed directly to the qualifying patient or to the qualifying patient's designated caregiver.

c. The date and time the cannabis or cannabis-infused product is to be dispensed.

<u>d.</u> The registry identification number of the medical cannabis center that dispensed the cannabis or cannabis-infused product.

"§ 90-113.132. North Carolina Cannabis Research Program.

(a) It is the intent of the General Assembly that The University of North Carolina System undertake objective, scientific research regarding the administration of cannabis or cannabis-infused products as part of medical treatment. The University of North Carolina shall create a program to be known as the North Carolina Cannabis Research Program.

(b) The research conducted under this section may involve the development of quality control, purity, and labeling standards for cannabis dispensed through the regulated medical cannabis supply system; sound advice and recommendations on the best practices for the safe and efficient cultivation of cannabis; and analysis of genetic and healing properties of the many varied strains of cannabis to determine which strains may be best suited for a particular condition or treatment.

"§ 90-113.134. North Carolina Medical Cannabis Program Fund.

There is established within the Department the North Carolina Medical Cannabis Program Fund to ensure the availability of funds necessary to carry out the Department's responsibilities under this Article. All monies collected pursuant to this Article shall be deposited into the Fund. The Fund shall be used for direct and indirect costs associated with the implementation, administration, and enforcement of this Article. Revenues generated in excess of the amount needed to implement, administer, and enforce this Article shall be annually distributed to the State General Fund.

"§ 90-113.136. Protections for the medical use of cannabis.

(a) A registry identification cardholder shall not be subject to arrest, prosecution, or penalty in any manner for the possession or purchase of cannabis for medical use by the qualified patient if the quantity of usable cannabis possessed or purchased does not exceed an adequate supply, as determined by the qualified patient's physician.

- (b) If usable cannabis is infused or added as an ingredient to an edible cannabis product, salve, tincture, or any other preparation to be consumed or used by a qualified patient, the weight of the other ingredients that are not usable cannabis shall not be included for the purpose of determining whether a qualified patient is in possession of an amount of cannabis that exceeds the qualified patient's adequate supply.
- (c) A supplier shall not be subject to arrest, prosecution, or penalty in any manner for producing, possessing, distributing, or dispensing cannabis or cannabis-infused products in a manner consistent with this Article.
- (d) Nothing in this Article shall be construed to extend the protections of this Article to any person, including a qualified patient, a designated caregiver, or a supplier, to allow that person to acquire, possess, manufacture, produce, use, sell, distribute, dispense, or transport cannabis in a manner that is not consistent with this Article.

"§ 90-113.138. Educational campaign.

- (a) The Department, in consultation with medical professionals, shall develop an educational campaign about the regulated medical cannabis supply system. The educational campaign shall be regularly advertised through television, online, or social media. The educational campaign must include:
 - (1) The debilitating medical conditions which may be treated with medical use.
 - (2) Potential benefits and risks of the use of cannabis and cannabis-infused products.
 - (3) A notification that cannabis and cannabis-infused products are for a qualifying patient's use only and that they should not be donated or otherwise supplied to another individual.
- (b) The Department shall make the information identified in subsection (a) of this section available online with a link to the information conspicuously located on the Department's website.
- "§ 90-113.140. Reserved for future codification purposes.
- "§ 90-113.142. Reserved for future codification purposes.

"§ 90-113.144. Annual report.

- (a) The Department, in consultation with the Commission and the Advisory Board, shall report annually on the effectiveness of the medical cannabis program operated pursuant to this Article and recommendations for any changes to the program. The report shall, without disclosing any identifying information about cardholders, physicians, qualified patients, designated caregivers, or suppliers, contain the following, at a minimum:
 - (1) The number of registry identification card applications submitted, approved, and renewed.
 - (2) The number of qualifying patients and designated caregivers served by each medical cannabis center during the report year.
 - (3) The nature of the debilitating medical conditions of the qualifying patients and a breakdown of qualifying patients by age group.
 - (4) The new debilitating medical conditions added by the Advisory Board, if any.
 - (5) The efficacy of or satisfaction with cannabis and cannabis-infused products on a yes-no questionnaire as submitted by qualifying patients in a voluntary, anonymous survey, which may be conducted online or through medical cannabis centers.
 - (6) The number of registry identification cards denied, suspended, or revoked.
 - (7) The number of physicians providing written certifications for qualifying patients.
 - (8) The number of suppliers, production facilities, and medical cannabis centers by county.

1 The report shall be submitted to the Joint Legislative Oversight Committee on Health (b) 2 and Human Services and to the Joint Legislative Oversight Committee on Justice and Public 3 Safety by October 1 of each year, beginning in 2022. 4 "§ 90-113.146. Construction of Article. 5 This Article shall not be construed to do any of the following: Allow for a violation of any law other than for conduct in compliance with the 6 (1) 7 provisions of this Article. 8 **(2)** Affect or repeal laws relating to nonmedical use, possession, production, or 9 sale of cannabis. 10 Authorize the use of cannabis by anyone other than a qualified patient. **(3)** 11 Permit the operation of any vehicle, aircraft, train, or boat while under the (4) influence of cannabis. 12 13 Require the violation of federal law or purport to give immunity under federal (5) 14 15 (6) Require any accommodation of any on-site medical use of cannabis in any correctional institution or detention facility or place of education or 16 17 employment, or of smoking or vaping cannabis in any public place. Require a health insurance provider, health care plan, property and casualty 18 <u>(7)</u> 19 insurer, or medical assistance program to be liable for or reimburse a claim 20 for the medical use of cannabis. Consultations in which physicians diagnose 21 debilitating medical conditions and complete written certifications shall be 22 reimbursed consistent with any other visit to a health care facility. 23 Affect or repeal laws relating to negligence or professional malpractice on the (8) 24 part of a qualified patient, designated caregiver, physician, supplier, or 25 supplier's agents or employees. 26 "§ 90-113.148. Severability. 27 The provisions of this Article are severable. If any provision of this Article is held invalid by a court of competent jurisdiction, the invalidity shall not affect other provisions of this Article 28 29 which can be given effect without the invalid provision." 30 **SECTION 2.** No later than 30 days after the effective date of this act, the North Carolina Medical Board shall approve a three-hour continuing medical education course and a 31 32 one-hour supplemental medical education course on cannabis and cannabis-infused products. 33 **SECTION 3.** G.S. 105-164.13 reads as rewritten: 34 "§ 105-164.13. Retail sales and use tax. 35 The sale at retail and the use, storage, or consumption in this State of the following items are 36 specifically exempted from the tax imposed by this Article: 37 38 (13e) Cannabis or cannabis-infused products sold by a medical cannabis center to a 39 registry identification cardholder. The terms "cannabis," "cannabis-infused 40 product," "medical cannabis center," and "registry identification cardholder" have the same meanings as defined in G.S. 90-113.114. 41 42 **SECTION 4.** G.S. 106-121 reads as rewritten: 43 "§ 106-121. Definitions and general consideration. 44 45 For the purpose of this Article:

The term "drug" means all of the following:

Articles recognized in the official United States Pharmacopoeia,

official Homeopathic Pharmacopoeia of the United States, or official

National Formulary, or any supplement to any of them; and them.

Senate Bill 711-Third Edition

(6)

46 47

48

49

1 Articles intended for use in the diagnosis, cure, mitigation, treatment b. 2 or prevention of disease in man or other animals; and animals, except 3 for cannabis-infused products, as defined in G.S. 90-113.114, that are 4 manufactured by a production facility or sold by a medical cannabis 5 center, as defined in G.S. 90-113.114. 6 Articles (other than food) intended to affect the structure or any c. function of the body of man or other animals; and animals. 7 8 d. Articles intended for use as a component of any article specified in 9 paragraphs a, b or c; but does not include devices or their components, 10 parts, or accessories. 11 12 (8)The term "food" means all of the following: Articles used for food or drink for man or other animals, except for 13 14 cannabis-infused products, as defined in G.S. 90-113.114, that are manufactured by a production facility or sold by a medical cannabis 15 center, as defined in G.S. 90-113.114. 16 17 Chewing gum, andgum. b. Articles used for components of any such article. 18 c. 19 20 **SECTION 5.** Sections 8.5(a) and 8.5(b) of S.L. 2015-154 are repealed. 21 **SECTION 5.5.** G.S. 90-87(16) reads as rewritten: 22 "Marijuana" means all parts of the plant of the genus Cannabis, whether 23 growing or not; the seeds thereof; the resin extracted from any part of such 24 plant; and every compound, manufacture, salt, derivative, mixture, or 25 preparation of such plant, its seeds or resin, but shall not include the mature 26 stalks of such plant, fiber produced from such stalks, oil, or cake made from the seeds of such plant, any other compound, manufacture, salt, derivative, 27 28 mixture, or preparation of such mature stalks (except the resin extracted 29 therefrom), fiber, oil, or cake, or the sterilized seed of such plant which is 30 incapable of germination. The term does not include industrial hemp as defined in G.S. 106-568.51, when the industrial hemp is produced and used in 31

SECTION 6. This act is effective when it becomes law and applies to acts committed on and after that date.

of Chapter 90 of the General Statutes."

compliance with rules issued by the North Carolina Industrial Hemp

Commission. The term does not include an adequate supply as defined in

G.S. 90-113.114 of cannabis for medical use in compliance with Article 5H

32

33

34

35

36